METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial

METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial

Purpose: Metformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression. Design: Parallel-group, multicenter, randomized phase...

Full description

Bibliographic Details
Main Authors: Liangbo Linus Shen, MD, Jeremy D. Keenan, MD, MPH, Noor Chahal, BS, Abu Tahir Taha, BS, Jasmeet Saroya, BS, Chu Jian Ma, MD, Mengyuan Sun, PhD, Daphne Yang, BS, Catherine Psaras, BA, Jacquelyn Callander, MD, Christina Flaxel, MD, Amani A. Fawzi, MD, Thomas K. Schlesinger, MD, PhD, Robert W. Wong, MD, Loh-Shan Bryan Leung, MD, Alexander M. Eaton, MD, Nathan C. Steinle, MD, David G. Telander, MD, Armin R. Afshar, MD, Melissa D. Neuwelt, MD, Jennifer I. Lim, MD, Glenn C. Yiu, MD, PhD, Jay M. Stewart, MD
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Ophthalmology Science
Subjects:
Age-related macular degeneration
Geographic atrophy
Metformin
Randomized controlled trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2666914523001720

Internet

http://www.sciencedirect.com/science/article/pii/S2666914523001720

Similar Items